# SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Source: https://onco.cc/trials/nct04977024/  
OnCo record `nct04977024` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of COVID-19 Vaccine in non-Hodgkin lymphoma and multiple myeloma, run by GeoVax, Inc., active and no longer recruiting.

## Summary

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer is a phase 2 interventional study registered as NCT04977024 by GeoVax, Inc., with 63 participants enrolled, started 2021-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: COVID-19 Vaccine and Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04977024
- Phase: 2
- Setting: A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
- Sponsor: GeoVax, Inc.
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT04977024: https://clinicaltrials.gov/study/NCT04977024

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct04977024.json